Customer Service
Mon-Fri 9am-5pm (EST)
Cernostics' lead product under development, TissueCypher™ Barrett’s Esophagus Assay, uses whole slide digital imaging technology to produce comprehensive risk prediction for the development of esophageal cancer in patients with Barrett's Esophagus. The TissueCypher™ Barrett’s Esophagus Assay will focus on eliminating uncertainty related to the treatment of Barrett's Esophagus and will provide actionable information to doctors and patients.
In addition to our lead product, Cernostics continues to evaluate clinical indications for which the TissueCypher™ platform can provide actionable clinical information. Examples of this ongoing work are provided below for lung, colon, and breast cancer. Roll over the images below to see the difference that TissueCypher™ can provide for whole slide image analysis.